Project Grant HT94252310203
Award Date
9/1/23
Completion Date
8/24/24
Dollars Obligated
$160K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...
This Project Grant award, totaling $486,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports research conducted by the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to target PRMT5 in MTAP-loss melanoma. The project aims to transform health care for Service Members and the public through innovative and impactful cancer research, with a focus on...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,882,607.00 to The University of Texas M.D. Anderson Cancer Center to conduct research titled "LEVERAGING PROSTATE CANCERS' UNIQUE LIPID METABOLISM TO INDUCE THERAPEUTIC FERROPTOSIS." The grant period runs from March 15, 2025 to March 14, 2028. The research aims to transform healthcare for military service members, veterans, and the...
The University of Texas MD Anderson Cancer Center was awarded a $1,214,999 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to identify collateral lethal targets in prostate cancer from September 1, 2021 through August 31, 2024. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...
The Department of the Army Medical Command awarded a $249,999 Project Grant to The University of Texas M.D. Anderson Cancer Center through the Military Medical Research and Development program. This three-year grant will fund research from September 2022 to August 2025 to revisit antiangiogenic therapy and target prostate cancer metabolism. The Military Medical Research and Development program, designated by CFDA #12.420, supports basic, applied, and advanced biomedical research with the goals...
This $1,124,825 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to identify novel therapeutic targets for aggressive prostate cancer through induced pluripotent stem cell modeling of BRCA2 mutant prostate tissue. The award, which runs from August 1, 2024 to July 31, 2027, will enable UTHSCSA to conduct innovative scientific...
This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $544,892 to the University of Texas Health Science Center at Houston to develop a novel peptide-drug conjugate for precision-targeted DNA damage in neuroendocrine tumors. The award commenced on August 1, 2025 and is set to conclude on July 31, 2028. The goal of this research is to transform healthcare for military service members, veterans, and the broader...
The University of Texas MD Anderson Cancer Center received a $1,007,007.84 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 2022 through September 2025 to investigate the complex immunological niche of bone metastasis and its role in therapy response and resistance. Through basic, applied, and advanced biomedical research efforts, the project...
This three-year Project Grant award of $739,289 from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) will fund research to revisit antiangiogenic therapy approaches to target prostate cancer metabolism. The University of Texas M.D. Anderson Cancer Center in Houston, Texas will lead the effort starting September 1, 2022. As part of the award, two co-investigators at Baylor College of Medicine will utilize mass spectrometry imaging to...